Skip to main content

Table 2 Worm burden reductions (WBRs) following different single oral doses of R, S-PZQ and PZQ

From: In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium

 

No. of hamsters cured/treated

Mean no. of alive worms ± SD

WBR (%)

Female WBR (%)

ED50 (mg/kg)

 

Liver

Mesenteric veins

Total

Females

Control

0/4

2.75 ± 3.8

31.0 ± 9.5

33.8 ± 16.8

15.3 ± 5.2

 

PZQ

 250.0 mg/kg

3/4

0.25 ± 0.5

0

0.3 ± 0.5

0

99.3

100

  

 200.0 mg/kgb

     

77.2

 

118.1

 150.0 mg/kgb

     

66.1

 

 100.0 mg/kgb

     

39.2

 

R-PZQ

 125.0 mg/kg

2/4

0.25 ± 0.5

0.25 ± 0.5

0.5 ± 0.6

0

98.5

100

24.7a

 

 62.5 mg/kg

1/4

5.0 ± 4.7

3.25 ± 3.6

8.3 ± 8.1

2.3 ± 3.3

75.6

85.2

 31.0 mg/kg

0/3

6.7 ± 11.5

2.3 ± 2.3

9.0 ± 13.9

4.0 ± 6.9

73.3

73.8

S-PZQ

 500.0 mg/kg

3/4

1.25 ± 2.5

0.75 ± 1.5

2.0 ± 4.0

0

94.1

100

127.6a

5.17c

 250.0 mg/kg

2/4

4.0 ± 4.9

1.75 ± 2.1

5.8 ± 6.9

0

83.0

100

 125.0 mg/kg

0/3

7.0 ± 6.2

11.0 ± 6.0

18.0 ± 12.1

0.7 ± 0.6

46.7

95.6

  1. aDetermined on total worm burden reductions
  2. bData reported by Webbe & James [18]
  3. cEudysmic ratio